The Migraine Drugs Market was valued at USD 6.81 Billion in 2024, and is projected to reach USD 13.34 Billion by 2030, rising at a CAGR of 10.90%. The market is largely driven by factors such as a rise in disease prevalence, development of novel therapies, lifestyle changes, and hormonal medications.
Migraine is a debilitating neurological disease characterized by recurrent attacks of severe throbbing head pain that can last for more than three days. Migraine pain may get worse on movement, preventing the patient from carrying out normal, day-to-day activities. In about one-third of attacks, both sides of the head, face, or neck are affected.
Over the past five years, the global migraine drugs market has been relatively stagnant, with the market mainly dominated by usage of generic triptans and other off-label drugs. Majority of the currently prescribed drugs for both acute and preventative treatment are associated with poor efficacy and an unfavorable side-effect profile.
Launch of Amgen/ Novartis’ CGRP mAb Aimovig and Teva Pharma’s Ajovy is the first step toward revolutionizing the treatment paradigm of migraine prevention. For drug manufacturers likely to enter the market by 2019, such as Eli Lilly, Alder BioPharma, and Biohaven Pharma, pricing will be a key differentiating factor as all CGRP-based therapies have a similar efficacy and safety profile.
This product will be delivered within 1-3 business days.
Migraine is a debilitating neurological disease characterized by recurrent attacks of severe throbbing head pain that can last for more than three days. Migraine pain may get worse on movement, preventing the patient from carrying out normal, day-to-day activities. In about one-third of attacks, both sides of the head, face, or neck are affected.
Over the past five years, the global migraine drugs market has been relatively stagnant, with the market mainly dominated by usage of generic triptans and other off-label drugs. Majority of the currently prescribed drugs for both acute and preventative treatment are associated with poor efficacy and an unfavorable side-effect profile.
Launch of Amgen/ Novartis’ CGRP mAb Aimovig and Teva Pharma’s Ajovy is the first step toward revolutionizing the treatment paradigm of migraine prevention. For drug manufacturers likely to enter the market by 2019, such as Eli Lilly, Alder BioPharma, and Biohaven Pharma, pricing will be a key differentiating factor as all CGRP-based therapies have a similar efficacy and safety profile.
Migraine Drugs Market Report Highlights
- Based on treatment, the preventive segment led the market with the largest revenue share of 62.03% in 2024. The Acute segment held the second largest market revenue share in 2024.
- Based on the therapeutic class, the CGRP monoclonal antibodies segment led the market with the largest revenue share of 56.68% in 2024. The CGRP small molecule antagonist diagnostics segment is anticipated to grow at the fastest CAGR over the forecast period.
- Based on the route of administration, the injectable segment led the market with the largest revenue share of 69.48% in 2024. The oral segment is projected to witness a significant CAGR over the forecast period.
- Based on age group, the adult segment led the market with the largest revenue share of 52.92% in 2024 and is anticipated to grow at a significant CAGR over the forecast period. The geriatric segment is anticipated to grow at a significant CAGR over the forecast period.
- Based on availability, the prescription drugs segment led the market with the largest revenue share of 62.38% in 2024 and is anticipated to grow at a significant CAGR over the forecast period.
Why Should You Buy This Report?
- Comprehensive Market Analysis: Gain detailed insights into the market across major regions and segments.
- Competitive Landscape: Explore the market presence of key players.
- Future Trends: Discover the pivotal trends and drivers shaping the future of the market.
- Actionable Recommendations: Utilize insights to uncover new revenue streams and guide strategic business decisions.
This report addresses:
- Market intelligence to enable effective decision-making
- Market estimates and forecasts from 2018 to 2030
- Growth opportunities and trend analyses
- Segment and regional revenue forecasts for market assessment
- Competition strategy and market share analysis
- Product innovation listings for you to stay ahead of the curve
This product will be delivered within 1-3 business days.
Table of Contents
Chapter 1. Methodology and Scope
1.1. Market Segmentation & Scope
1.2. Segment Definitions
1.2.1. Treatment
1.2.2. Therapeutic Class
1.2.3. Route of Administration
1.2.4. Age Group
1.2.5. Availability
1.2.6. Regional scope
1.2.7. Estimates and forecasts timeline
1.3. Research Methodology
1.4. Information Procurement
1.4.1. Purchased database
1.4.2. internal database
1.4.3. Secondary sources
1.4.4. Primary research
1.4.5. Details of primary research
1.4.5.1. Data for primary interviews in North America
1.4.5.2. Data for primary interviews in Europe
1.4.5.3. Data for primary interviews in Asia Pacific
1.4.5.4. Data for primary interviews in Latin America
1.4.5.5. Data for Primary interviews in MEA
1.5. Information or Data Analysis
1.5.1. Data analysis models
1.6. Market Formulation & Validation
1.7. Model Details
1.7.1. Commodity flow analysis (Model 1)
1.7.2. Approach 1: Commodity flow approach
1.7.3. Volume price analysis (Model 2)
1.7.4. Approach 2: Volume price analysis
1.8. List of Secondary Sources
1.9. List of Primary Sources
1.10. Objectives
1.2. Segment Definitions
1.2.1. Treatment
1.2.2. Therapeutic Class
1.2.3. Route of Administration
1.2.4. Age Group
1.2.5. Availability
1.2.6. Regional scope
1.2.7. Estimates and forecasts timeline
1.3. Research Methodology
1.4. Information Procurement
1.4.1. Purchased database
1.4.2. internal database
1.4.3. Secondary sources
1.4.4. Primary research
1.4.5. Details of primary research
1.4.5.1. Data for primary interviews in North America
1.4.5.2. Data for primary interviews in Europe
1.4.5.3. Data for primary interviews in Asia Pacific
1.4.5.4. Data for primary interviews in Latin America
1.4.5.5. Data for Primary interviews in MEA
1.5. Information or Data Analysis
1.5.1. Data analysis models
1.6. Market Formulation & Validation
1.7. Model Details
1.7.1. Commodity flow analysis (Model 1)
1.7.2. Approach 1: Commodity flow approach
1.7.3. Volume price analysis (Model 2)
1.7.4. Approach 2: Volume price analysis
1.8. List of Secondary Sources
1.9. List of Primary Sources
1.10. Objectives
Chapter 2. Executive Summary
2.1. Market Outlook
2.2. Segment Outlook
2.2.1. Treatment and Therapeutic Class outlook
2.2.2. Route of Administration outlook
2.2.3. Age Group and Availability outlook
2.2.4. Regional outlook
2.3. Competitive Insights
2.2. Segment Outlook
2.2.1. Treatment and Therapeutic Class outlook
2.2.2. Route of Administration outlook
2.2.3. Age Group and Availability outlook
2.2.4. Regional outlook
2.3. Competitive Insights
Chapter 3. Migraine Drugs Market Variables, Trends & Scope
3.1. Market Lineage Outlook
3.1.1. Parent market outlook
3.1.2. Related/ancillary market outlook
3.2. Market Dynamics
3.2.1. Market driver analysis
3.2.1.1. Increasing prevalence of migraines
3.2.1.2. Advancements in drug development
3.2.1.3. Growing awareness and diagnosis
3.2.2. Market restraint analysis
3.2.2.1. High cost of development
3.2.2.2. Regulatory challenges for new drug approvals
3.3. Migraine Drugs Market Analysis Tools
3.3.1. Industry Analysis - Porter’s
3.3.1.1. Supplier power
3.3.1.2. Buyer power
3.3.1.3. Substitution threat
3.3.1.4. Threat of new entrant
3.3.1.5. Competitive rivalry
3.3.2. PESTEL Analysis
3.3.2.1. Political landscape
3.3.2.2. Technological landscape
3.3.2.3. Economic landscape
3.4. Pricing Analysis
3.5. Pipeline Analysis, by Phase
3.1.1. Parent market outlook
3.1.2. Related/ancillary market outlook
3.2. Market Dynamics
3.2.1. Market driver analysis
3.2.1.1. Increasing prevalence of migraines
3.2.1.2. Advancements in drug development
3.2.1.3. Growing awareness and diagnosis
3.2.2. Market restraint analysis
3.2.2.1. High cost of development
3.2.2.2. Regulatory challenges for new drug approvals
3.3. Migraine Drugs Market Analysis Tools
3.3.1. Industry Analysis - Porter’s
3.3.1.1. Supplier power
3.3.1.2. Buyer power
3.3.1.3. Substitution threat
3.3.1.4. Threat of new entrant
3.3.1.5. Competitive rivalry
3.3.2. PESTEL Analysis
3.3.2.1. Political landscape
3.3.2.2. Technological landscape
3.3.2.3. Economic landscape
3.4. Pricing Analysis
3.5. Pipeline Analysis, by Phase
Chapter 4. Migraine Drugs Market: Treatment Estimates & Trend Analysis
4.1. Global Migraine Drugs Market: Treatment Dashboard
4.2. Global Migraine Drugs Market: Treatment Movement Analysis
4.3. Global Migraine Drugs Market by Treatment, Revenue
4.4. Acute
4.4.1. Acute market estimates and forecasts, 2018 to 2030 (USD Million)
4.5. Preventive
4.5.1. Preventive market estimates and forecasts, 2018 to 2030 (USD Million)
4.2. Global Migraine Drugs Market: Treatment Movement Analysis
4.3. Global Migraine Drugs Market by Treatment, Revenue
4.4. Acute
4.4.1. Acute market estimates and forecasts, 2018 to 2030 (USD Million)
4.5. Preventive
4.5.1. Preventive market estimates and forecasts, 2018 to 2030 (USD Million)
Chapter 5. Migraine Drugs Market: Therapeutic Class Estimates & Trend Analysis
5.1. Global Migraine Drugs Market: Therapeutic Class Dashboard
5.2. Global Migraine Drugs Market: Therapeutic Class Movement Analysis
5.3. Global Migraine Drugs Market by Therapeutic Class, Revenue
5.4. CGRP monoclonal antibodies
5.4.1. CGRP monoclonal antibodies market estimates and forecasts, 2018 to 2030 (USD Million)
5.5. CGRP small molecule antagonists
5.5.1. CGRP small molecule antagonists market estimates and forecasts, 2018 to 2030 (USD Million)
5.6. Acetylcholine inhibitors/ neurotoxins
5.6.1. Acetylcholine inhibitors/ neurotoxins market estimates and forecasts, 2018 to 2030 (USD Million)
5.7. Triptans
5.7.1. Triptans market estimates and forecasts, 2018 to 2030 (USD Million)
5.8. Ditans
5.8.1. Ditans market estimates and forecasts, 2018 to 2030 (USD Million)
5.9. Ergot alkaloids
5.9.1. Ergot alkaloids market estimates and forecasts, 2018 to 2030 (USD Million)
5.10. NSAIDs
5.10.1. NSAIDs market estimates and forecasts, 2018 to 2030 (USD Million)
5.11. Others
5.11.1. Others market estimates and forecasts, 2018 to 2030 (USD Million)
5.2. Global Migraine Drugs Market: Therapeutic Class Movement Analysis
5.3. Global Migraine Drugs Market by Therapeutic Class, Revenue
5.4. CGRP monoclonal antibodies
5.4.1. CGRP monoclonal antibodies market estimates and forecasts, 2018 to 2030 (USD Million)
5.5. CGRP small molecule antagonists
5.5.1. CGRP small molecule antagonists market estimates and forecasts, 2018 to 2030 (USD Million)
5.6. Acetylcholine inhibitors/ neurotoxins
5.6.1. Acetylcholine inhibitors/ neurotoxins market estimates and forecasts, 2018 to 2030 (USD Million)
5.7. Triptans
5.7.1. Triptans market estimates and forecasts, 2018 to 2030 (USD Million)
5.8. Ditans
5.8.1. Ditans market estimates and forecasts, 2018 to 2030 (USD Million)
5.9. Ergot alkaloids
5.9.1. Ergot alkaloids market estimates and forecasts, 2018 to 2030 (USD Million)
5.10. NSAIDs
5.10.1. NSAIDs market estimates and forecasts, 2018 to 2030 (USD Million)
5.11. Others
5.11.1. Others market estimates and forecasts, 2018 to 2030 (USD Million)
Chapter 6. Migraine Drugs Market: Route of Administration Estimates & Trend Analysis
6.1. Global Migraine Drugs Market: Route of Administration Dashboard
6.2. Global Migraine Drugs Market: Route of Administration Movement Analysis
6.3. Global Migraine Drugs Market by Route of Administration, Revenue
6.4. Oral
6.4.1. Oral market estimates and forecasts, 2018 to 2030 (USD Million)
6.5. Injectable
6.5.1. Injectable market estimates and forecasts, 2018 to 2030 (USD Million)
6.6. Others
6.6.1. Others market estimates and forecasts, 2018 to 2030 (USD Million)
6.2. Global Migraine Drugs Market: Route of Administration Movement Analysis
6.3. Global Migraine Drugs Market by Route of Administration, Revenue
6.4. Oral
6.4.1. Oral market estimates and forecasts, 2018 to 2030 (USD Million)
6.5. Injectable
6.5.1. Injectable market estimates and forecasts, 2018 to 2030 (USD Million)
6.6. Others
6.6.1. Others market estimates and forecasts, 2018 to 2030 (USD Million)
Chapter 7. Migraine Drugs Market: Age Group Estimates & Trend Analysis
7.1. Global Migraine Drugs Market: Age Group Dashboard
7.2. Global Migraine Drugs Market: Age Group Movement Analysis
7.3. Global Migraine Drugs Market by Age Group, Revenue
7.4. Pediatric
7.4.1. Pediatric market estimates and forecasts, 2018 to 2030 (USD Million)
7.5. Adult
7.5.1. Adult market estimates and forecasts, 2018 to 2030 (USD Million)
7.6. Geriatric
7.6.1. Geriatric market estimates and forecasts, 2018 to 2030 (USD Million)
7.2. Global Migraine Drugs Market: Age Group Movement Analysis
7.3. Global Migraine Drugs Market by Age Group, Revenue
7.4. Pediatric
7.4.1. Pediatric market estimates and forecasts, 2018 to 2030 (USD Million)
7.5. Adult
7.5.1. Adult market estimates and forecasts, 2018 to 2030 (USD Million)
7.6. Geriatric
7.6.1. Geriatric market estimates and forecasts, 2018 to 2030 (USD Million)
Chapter 8. Migraine Drugs Market: Availability Estimates & Trend Analysis
8.1. Global Migraine Drugs Market: Availability Dashboard
8.2. Global Migraine Drugs Market: Availability Movement Analysis
8.3. Global Migraine Drugs Market by Availability, Revenue
8.4. Prescription Drugs
8.4.1. Prescription Drugs market estimates and forecasts, 2018 to 2030 (USD Million)
8.5. Over-The-Counter (OTC) Drugs
8.5.1. Over-The-Counter (OTC) Drugs market estimates and forecasts, 2018 to 2030 (USD Million)
8.2. Global Migraine Drugs Market: Availability Movement Analysis
8.3. Global Migraine Drugs Market by Availability, Revenue
8.4. Prescription Drugs
8.4.1. Prescription Drugs market estimates and forecasts, 2018 to 2030 (USD Million)
8.5. Over-The-Counter (OTC) Drugs
8.5.1. Over-The-Counter (OTC) Drugs market estimates and forecasts, 2018 to 2030 (USD Million)
Chapter 9. Migraine Drugs Market: Regional Estimates & Trend Analysis by Treatment, Therapeutic Class, and Route of Administration
9.1. Regional Dashboard
9.2. Market Size, & Forecasts Trend Analysis, 2018 to 2030:
9.3. North America
9.3.1. U.S.
9.3.1.1. Key country dynamics
9.3.1.2. Regulatory framework/ reimbursement structure
9.3.1.3. Competitive scenario
9.3.1.4. U.S. market estimates and forecasts, 2018 to 2030 (USD Million)
9.3.2. Canada
9.3.2.1. Key country dynamics
9.3.2.2. Regulatory framework/ reimbursement structure
9.3.2.3. Competitive scenario
9.3.2.4. Canada market estimates and forecasts, 2018 to 2030 (USD Million)
9.3.3. Mexico
9.3.3.1. Key country dynamics
9.3.3.2. Regulatory framework/ reimbursement structure
9.3.3.3. Competitive scenario
9.3.3.4. Mexico market estimates and forecasts, 2018 to 2030 (USD Million)
9.4. Europe
9.4.1. UK
9.4.1.1. Key country dynamics
9.4.1.2. Regulatory framework/ reimbursement structure
9.4.1.3. Competitive scenario
9.4.1.4. UK market estimates and forecasts, 2018 to 2030 (USD Million)
9.4.2. Germany
9.4.2.1. Key country dynamics
9.4.2.2. Regulatory framework/ reimbursement structure
9.4.2.3. Competitive scenario
9.4.2.4. Germany market estimates and forecasts, 2018 to 2030 (USD Million)
9.4.3. France
9.4.3.1. Key country dynamics
9.4.3.2. Regulatory framework/ reimbursement structure
9.4.3.3. Competitive scenario
9.4.3.4. France market estimates and forecasts, 2018 to 2030 (USD Million)
9.4.4. Italy
9.4.4.1. Key country dynamics
9.4.4.2. Regulatory framework/ reimbursement structure
9.4.4.3. Competitive scenario
9.4.4.4. Italy market estimates and forecasts, 2018 to 2030 (USD Million)
9.4.5. Spain
9.4.5.1. Key country dynamics
9.4.5.2. Regulatory framework/ reimbursement structure
9.4.5.3. Competitive scenario
9.4.5.4. Spain market estimates and forecasts, 2018 to 2030 (USD Million)
9.4.6. Norway
9.4.6.1. Key country dynamics
9.4.6.2. Regulatory framework/ reimbursement structure
9.4.6.3. Competitive scenario
9.4.6.4. Norway market estimates and forecasts, 2018 to 2030 (USD Million)
9.4.7. Sweden
9.4.7.1. Key country dynamics
9.4.7.2. Regulatory framework/ reimbursement structure
9.4.7.3. Competitive scenario
9.4.7.4. Sweden market estimates and forecasts, 2018 to 2030 (USD Million)
9.4.8. Denmark
9.4.8.1. Key country dynamics
9.4.8.2. Regulatory framework/ reimbursement structure
9.4.8.3. Competitive scenario
9.4.8.4. Denmark market estimates and forecasts, 2018 to 2030 (USD Million)
9.5. Asia Pacific
9.5.1. Japan
9.5.1.1. Key country dynamics
9.5.1.2. Regulatory framework/ reimbursement structure
9.5.1.3. Competitive scenario
9.5.1.4. Japan market estimates and forecasts, 2018 to 2030 (USD Million)
9.5.2. China
9.5.2.1. Key country dynamics
9.5.2.2. Regulatory framework/ reimbursement structure
9.5.2.3. Competitive scenario
9.5.2.4. China market estimates and forecasts, 2018 to 2030 (USD Million)
9.5.3. India
9.5.3.1. Key country dynamics
9.5.3.2. Regulatory framework/ reimbursement structure
9.5.3.3. Competitive scenario
9.5.3.4. India market estimates and forecasts, 2018 to 2030 (USD Million)
9.5.4. Australia
9.5.4.1. Key country dynamics
9.5.4.2. Regulatory framework/ reimbursement structure
9.5.4.3. Competitive scenario
9.5.4.4. Australia market estimates and forecasts, 2018 to 2030 (USD Million)
9.5.5. South Korea
9.5.5.1. Key country dynamics
9.5.5.2. Regulatory framework/ reimbursement structure
9.5.5.3. Competitive scenario
9.5.5.4. South Korea market estimates and forecasts, 2018 to 2030 (USD Million)
9.5.6. Thailand
9.5.6.1. Key country dynamics
9.5.6.2. Regulatory framework/ reimbursement structure
9.5.6.3. Competitive scenario
9.5.6.4. Thailand market estimates and forecasts, 2018 to 2030 (USD Million)
9.6. Latin America
9.6.1. Brazil
9.6.1.1. Key country dynamics
9.6.1.2. Regulatory framework/ reimbursement structure
9.6.1.3. Competitive scenario
9.6.1.4. Brazil market estimates and forecasts, 2018 to 2030 (USD Million)
9.6.2. Argentina
9.6.2.1. Key country dynamics
9.6.2.2. Regulatory framework/ reimbursement structure
9.6.2.3. Competitive scenario
9.6.2.4. Argentina market estimates and forecasts, 2018 to 2030 (USD Million)
9.7. Middle East & Africa
9.7.1. South Africa
9.7.1.1. Key country dynamics
9.7.1.2. Regulatory framework/ reimbursement structure
9.7.1.3. Competitive scenario
9.7.1.4. South Africa market estimates and forecasts, 2018 to 2030 (USD Million)
9.7.2. Saudi Arabia
9.7.2.1. Key country dynamics
9.7.2.2. Regulatory framework/ reimbursement structure
9.7.2.3. Competitive scenario
9.7.2.4. Saudi Arabia market estimates and forecasts, 2018 to 2030 (USD Million)
9.7.3. UAE
9.7.3.1. Key country dynamics
9.7.3.2. Regulatory framework/ reimbursement structure
9.7.3.3. Competitive scenario
9.7.3.4. UAE market estimates and forecasts, 2018 to 2030 (USD Million)
9.7.4. Kuwait
9.7.4.1. Key country dynamics
9.7.4.2. Regulatory framework/ reimbursement structure
9.7.4.3. Competitive scenario
9.7.4.4. Kuwait market estimates and forecasts, 2018 to 2030 (USD Million)
9.2. Market Size, & Forecasts Trend Analysis, 2018 to 2030:
9.3. North America
9.3.1. U.S.
9.3.1.1. Key country dynamics
9.3.1.2. Regulatory framework/ reimbursement structure
9.3.1.3. Competitive scenario
9.3.1.4. U.S. market estimates and forecasts, 2018 to 2030 (USD Million)
9.3.2. Canada
9.3.2.1. Key country dynamics
9.3.2.2. Regulatory framework/ reimbursement structure
9.3.2.3. Competitive scenario
9.3.2.4. Canada market estimates and forecasts, 2018 to 2030 (USD Million)
9.3.3. Mexico
9.3.3.1. Key country dynamics
9.3.3.2. Regulatory framework/ reimbursement structure
9.3.3.3. Competitive scenario
9.3.3.4. Mexico market estimates and forecasts, 2018 to 2030 (USD Million)
9.4. Europe
9.4.1. UK
9.4.1.1. Key country dynamics
9.4.1.2. Regulatory framework/ reimbursement structure
9.4.1.3. Competitive scenario
9.4.1.4. UK market estimates and forecasts, 2018 to 2030 (USD Million)
9.4.2. Germany
9.4.2.1. Key country dynamics
9.4.2.2. Regulatory framework/ reimbursement structure
9.4.2.3. Competitive scenario
9.4.2.4. Germany market estimates and forecasts, 2018 to 2030 (USD Million)
9.4.3. France
9.4.3.1. Key country dynamics
9.4.3.2. Regulatory framework/ reimbursement structure
9.4.3.3. Competitive scenario
9.4.3.4. France market estimates and forecasts, 2018 to 2030 (USD Million)
9.4.4. Italy
9.4.4.1. Key country dynamics
9.4.4.2. Regulatory framework/ reimbursement structure
9.4.4.3. Competitive scenario
9.4.4.4. Italy market estimates and forecasts, 2018 to 2030 (USD Million)
9.4.5. Spain
9.4.5.1. Key country dynamics
9.4.5.2. Regulatory framework/ reimbursement structure
9.4.5.3. Competitive scenario
9.4.5.4. Spain market estimates and forecasts, 2018 to 2030 (USD Million)
9.4.6. Norway
9.4.6.1. Key country dynamics
9.4.6.2. Regulatory framework/ reimbursement structure
9.4.6.3. Competitive scenario
9.4.6.4. Norway market estimates and forecasts, 2018 to 2030 (USD Million)
9.4.7. Sweden
9.4.7.1. Key country dynamics
9.4.7.2. Regulatory framework/ reimbursement structure
9.4.7.3. Competitive scenario
9.4.7.4. Sweden market estimates and forecasts, 2018 to 2030 (USD Million)
9.4.8. Denmark
9.4.8.1. Key country dynamics
9.4.8.2. Regulatory framework/ reimbursement structure
9.4.8.3. Competitive scenario
9.4.8.4. Denmark market estimates and forecasts, 2018 to 2030 (USD Million)
9.5. Asia Pacific
9.5.1. Japan
9.5.1.1. Key country dynamics
9.5.1.2. Regulatory framework/ reimbursement structure
9.5.1.3. Competitive scenario
9.5.1.4. Japan market estimates and forecasts, 2018 to 2030 (USD Million)
9.5.2. China
9.5.2.1. Key country dynamics
9.5.2.2. Regulatory framework/ reimbursement structure
9.5.2.3. Competitive scenario
9.5.2.4. China market estimates and forecasts, 2018 to 2030 (USD Million)
9.5.3. India
9.5.3.1. Key country dynamics
9.5.3.2. Regulatory framework/ reimbursement structure
9.5.3.3. Competitive scenario
9.5.3.4. India market estimates and forecasts, 2018 to 2030 (USD Million)
9.5.4. Australia
9.5.4.1. Key country dynamics
9.5.4.2. Regulatory framework/ reimbursement structure
9.5.4.3. Competitive scenario
9.5.4.4. Australia market estimates and forecasts, 2018 to 2030 (USD Million)
9.5.5. South Korea
9.5.5.1. Key country dynamics
9.5.5.2. Regulatory framework/ reimbursement structure
9.5.5.3. Competitive scenario
9.5.5.4. South Korea market estimates and forecasts, 2018 to 2030 (USD Million)
9.5.6. Thailand
9.5.6.1. Key country dynamics
9.5.6.2. Regulatory framework/ reimbursement structure
9.5.6.3. Competitive scenario
9.5.6.4. Thailand market estimates and forecasts, 2018 to 2030 (USD Million)
9.6. Latin America
9.6.1. Brazil
9.6.1.1. Key country dynamics
9.6.1.2. Regulatory framework/ reimbursement structure
9.6.1.3. Competitive scenario
9.6.1.4. Brazil market estimates and forecasts, 2018 to 2030 (USD Million)
9.6.2. Argentina
9.6.2.1. Key country dynamics
9.6.2.2. Regulatory framework/ reimbursement structure
9.6.2.3. Competitive scenario
9.6.2.4. Argentina market estimates and forecasts, 2018 to 2030 (USD Million)
9.7. Middle East & Africa
9.7.1. South Africa
9.7.1.1. Key country dynamics
9.7.1.2. Regulatory framework/ reimbursement structure
9.7.1.3. Competitive scenario
9.7.1.4. South Africa market estimates and forecasts, 2018 to 2030 (USD Million)
9.7.2. Saudi Arabia
9.7.2.1. Key country dynamics
9.7.2.2. Regulatory framework/ reimbursement structure
9.7.2.3. Competitive scenario
9.7.2.4. Saudi Arabia market estimates and forecasts, 2018 to 2030 (USD Million)
9.7.3. UAE
9.7.3.1. Key country dynamics
9.7.3.2. Regulatory framework/ reimbursement structure
9.7.3.3. Competitive scenario
9.7.3.4. UAE market estimates and forecasts, 2018 to 2030 (USD Million)
9.7.4. Kuwait
9.7.4.1. Key country dynamics
9.7.4.2. Regulatory framework/ reimbursement structure
9.7.4.3. Competitive scenario
9.7.4.4. Kuwait market estimates and forecasts, 2018 to 2030 (USD Million)
Chapter 10. Competitive Landscape
10.1. Recent Developments & Impact Analysis, by Key Market Participants
10.2. Company/Competition Categorization
10.3. Vendor Landscape
10.3.1. List of key distributors and channel partners
10.3.2. Key customers
10.3.3. Key company market share analysis, 2023
10.3.4. AbbVie Inc.
10.3.4.1. Company overview
10.3.4.2. Financial performance
10.3.4.3. Product benchmarking
10.3.4.4. Strategic initiatives
10.3.5. Amgen Inc.
10.3.5.1. Company overview
10.3.5.2. Financial performance
10.3.5.3. Product benchmarking
10.3.5.4. Strategic initiatives
10.3.6. Teva Pharmaceutical Industries Ltd.
10.3.6.1. Company overview
10.3.6.2. Financial performance
10.3.6.3. Product benchmarking
10.3.6.4. Strategic initiatives
10.3.7. GSK plc
10.3.7.1. Company overview
10.3.7.2. Financial performance
10.3.7.3. Product benchmarking
10.3.7.4. Strategic initiatives
10.3.8. Eli Lilly and Company
10.3.8.1. Company overview
10.3.8.2. Financial performance
10.3.8.3. Product benchmarking
10.3.8.4. Strategic initiatives
10.3.9. Pfizer Inc.
10.3.9.1. Company overview
10.3.9.2. Financial performance
10.3.9.3. Product benchmarking
10.3.9.4. Strategic initiatives
10.3.10. Bausch Health Companies Inc.
10.3.10.1. Company overview
10.3.10.2. Financial performance
10.3.10.3. Product benchmarking
10.3.10.4. Strategic initiatives
10.3.11. Gensco Pharma
10.3.11.1. Company overview
10.3.11.2. Financial performance
10.3.11.3. Product benchmarking
10.3.11.4. Strategic initiatives
10.3.12. Impel Pharmaceuticals Inc.
10.3.12.1. Company overview
10.3.12.2. Financial performance
10.3.12.3. Product benchmarking
10.3.12.4. Strategic initiatives
10.3.13. Currax Pharmaceuticals LLC.
10.3.13.1. Company overview
10.3.13.2. Financial performance
10.3.13.3. Product benchmarking
10.3.13.4. Strategic initiatives
10.3.14. Lundbeck
10.3.14.1. Company overview
10.3.14.2. Financial performance
10.3.14.3. Product benchmarking
10.3.14.4. Strategic initiatives
10.2. Company/Competition Categorization
10.3. Vendor Landscape
10.3.1. List of key distributors and channel partners
10.3.2. Key customers
10.3.3. Key company market share analysis, 2023
10.3.4. AbbVie Inc.
10.3.4.1. Company overview
10.3.4.2. Financial performance
10.3.4.3. Product benchmarking
10.3.4.4. Strategic initiatives
10.3.5. Amgen Inc.
10.3.5.1. Company overview
10.3.5.2. Financial performance
10.3.5.3. Product benchmarking
10.3.5.4. Strategic initiatives
10.3.6. Teva Pharmaceutical Industries Ltd.
10.3.6.1. Company overview
10.3.6.2. Financial performance
10.3.6.3. Product benchmarking
10.3.6.4. Strategic initiatives
10.3.7. GSK plc
10.3.7.1. Company overview
10.3.7.2. Financial performance
10.3.7.3. Product benchmarking
10.3.7.4. Strategic initiatives
10.3.8. Eli Lilly and Company
10.3.8.1. Company overview
10.3.8.2. Financial performance
10.3.8.3. Product benchmarking
10.3.8.4. Strategic initiatives
10.3.9. Pfizer Inc.
10.3.9.1. Company overview
10.3.9.2. Financial performance
10.3.9.3. Product benchmarking
10.3.9.4. Strategic initiatives
10.3.10. Bausch Health Companies Inc.
10.3.10.1. Company overview
10.3.10.2. Financial performance
10.3.10.3. Product benchmarking
10.3.10.4. Strategic initiatives
10.3.11. Gensco Pharma
10.3.11.1. Company overview
10.3.11.2. Financial performance
10.3.11.3. Product benchmarking
10.3.11.4. Strategic initiatives
10.3.12. Impel Pharmaceuticals Inc.
10.3.12.1. Company overview
10.3.12.2. Financial performance
10.3.12.3. Product benchmarking
10.3.12.4. Strategic initiatives
10.3.13. Currax Pharmaceuticals LLC.
10.3.13.1. Company overview
10.3.13.2. Financial performance
10.3.13.3. Product benchmarking
10.3.13.4. Strategic initiatives
10.3.14. Lundbeck
10.3.14.1. Company overview
10.3.14.2. Financial performance
10.3.14.3. Product benchmarking
10.3.14.4. Strategic initiatives
List of Tables
Table 1. List of abbreviation
Table 2. North America Migraine Drugs market, by region, (USD Million) 2018-2030 (USD Million)
Table 3. North America Migraine Drugs market, by Treatment, (USD Million) 2018-2030 (USD Million)
Table 4. North America Migraine Drugs market, by Therapeutic Class, (USD Million) 2018-2030 (USD Million)
Table 5. North America Migraine Drugs market, by Route of Administration, (USD Million) 2018-2030 (USD Million)
Table 6. North America Migraine Drugs market, by Age Group, (USD Million) 2018-2030 (USD Million)
Table 7. North America Migraine Drugs market, by Availability, (USD Million) 2018-2030 (USD Million)
Table 8. U.S. Migraine Drugs market, by Treatment, (USD Million) 2018-2030 (USD Million)
Table 9. U.S. Migraine Drugs market, by Therapeutic Class, (USD Million) 2018-2030 (USD Million)
Table 10. U.S. Migraine Drugs market, by Route of Administration, (USD Million) 2018-2030 (USD Million)
Table 11. U.S. Migraine Drugs market, by Age Group, (USD Million) 2018-2030 (USD Million)
Table 12. U.S. Migraine Drugs market, by Availability, (USD Million) 2018-2030 (USD Million)
Table 13. Canada Migraine Drugs market, by Treatment, (USD Million) 2018-2030 (USD Million)
Table 14. Canada Migraine Drugs market, by Therapeutic Class, (USD Million) 2018-2030 (USD Million)
Table 15. Canada Migraine Drugs market, by Route of Administration, (USD Million) 2018-2030 (USD Million)
Table 16. Canada Migraine Drugs market, by Age Group, (USD Million) 2018-2030 (USD Million)
Table 17. Canada Migraine Drugs market, by Availability, (USD Million) 2018-2030 (USD Million)
Table 18. Europe Migraine Drugs market, by region, (USD Million) 2018-2030 (USD Million)
Table 19. Europe Migraine Drugs market, by Treatment, (USD Million) 2018-2030 (USD Million)
Table 20. Europe Migraine Drugs market, by Therapeutic Class, (USD Million) 2018-2030 (USD Million)
Table 21. Europe Migraine Drugs market, by Route of Administration, (USD Million) 2018-2030 (USD Million)
Table 22. Europe Migraine Drugs market, by Age Group, (USD Million) 2018-2030 (USD Million)
Table 23. Europe Migraine Drugs market, by Availability, (USD Million) 2018-2030 (USD Million)
Table 24. Germany Migraine Drugs market, by Treatment, (USD Million) 2018-2030 (USD Million)
Table 25. Germany Migraine Drugs market, by Therapeutic Class, (USD Million) 2018-2030 (USD Million)
Table 26. Germany Migraine Drugs market, by Route of Administration, (USD Million) 2018-2030 (USD Million)
Table 27. Germany Migraine Drugs market, by Age Group, (USD Million) 2018-2030 (USD Million)
Table 28. Germany Migraine Drugs market, by Availability, (USD Million) 2018-2030 (USD Million)
Table 29. UK Migraine Drugs market, by Treatment, (USD Million) 2018-2030 (USD Million)
Table 30. UK Migraine Drugs market, by Therapeutic Class, (USD Million) 2018-2030 (USD Million)
Table 31. UK Migraine Drugs market, by Route of Administration, (USD Million) 2018-2030 (USD Million)
Table 32. UK Migraine Drugs market, by Age Group, (USD Million) 2018-2030 (USD Million)
Table 33. UK Migraine Drugs market, by Availability, (USD Million) 2018-2030 (USD Million)
Table 34. France Migraine Drugs market, by Treatment, (USD Million) 2018-2030 (USD Million)
Table 35. France Migraine Drugs market, by Therapeutic Class, (USD Million) 2018-2030 (USD Million)
Table 36. France Migraine Drugs market, by Route of Administration, (USD Million) 2018-2030 (USD Million)
Table 37. France Migraine Drugs market, by Age Group, (USD Million) 2018-2030 (USD Million)
Table 38. France Migraine Drugs market, by Availability, (USD Million) 2018-2030 (USD Million)
Table 39. Italy Migraine Drugs market, by Treatment, (USD Million) 2018-2030 (USD Million)
Table 40. Italy Migraine Drugs market, by Therapeutic Class, (USD Million) 2018-2030 (USD Million)
Table 41. Italy Migraine Drugs market, by Route of Administration, (USD Million) 2018-2030 (USD Million)
Table 42. Italy Migraine Drugs market, by Age Group, (USD Million) 2018-2030 (USD Million)
Table 43. Italy Migraine Drugs market, by Availability, (USD Million) 2018-2030 (USD Million)
Table 44. Spain Migraine Drugs market, by Treatment, (USD Million) 2018-2030 (USD Million)
Table 45. Spain Migraine Drugs market, by Therapeutic Class, (USD Million) 2018-2030 (USD Million)
Table 46. Spain Migraine Drugs market, by Route of Administration, (USD Million) 2018-2030 (USD Million)
Table 47. Spain Migraine Drugs market, by Age Group, (USD Million) 2018-2030 (USD Million)
Table 48. Spain Migraine Drugs market, by Availability, (USD Million) 2018-2030 (USD Million)
Table 49. Denmark Migraine Drugs market, by Treatment, (USD Million) 2018-2030 (USD Million)
Table 50. Denmark Migraine Drugs market, by Therapeutic Class, (USD Million) 2018-2030 (USD Million)
Table 51. Denmark Migraine Drugs market, by Route of Administration, (USD Million) 2018-2030 (USD Million)
Table 52. Denmark Migraine Drugs market, by Age Group, (USD Million) 2018-2030 (USD Million)
Table 53. Denmark Migraine Drugs market, by Availability, (USD Million) 2018-2030 (USD Million)
Table 54. Sweden Migraine Drugs market, by Treatment, (USD Million) 2018-2030 (USD Million)
Table 55. Sweden Migraine Drugs market, by Therapeutic Class, (USD Million) 2018-2030 (USD Million)
Table 56. Sweden Migraine Drugs market, by Route of Administration, (USD Million) 2018-2030 (USD Million)
Table 57. Sweden Migraine Drugs market, by Age Group, (USD Million) 2018-2030 (USD Million)
Table 58. Sweden Migraine Drugs market, by Availability, (USD Million) 2018-2030 (USD Million)
Table 59. Norway Migraine Drugs market, by Treatment, (USD Million) 2018-2030 (USD Million)
Table 60. Norway Migraine Drugs market, by Therapeutic Class, (USD Million) 2018-2030 (USD Million)
Table 61. Norway Migraine Drugs market, by Route of Administration, (USD Million) 2018-2030 (USD Million)
Table 62. Norway Migraine Drugs market, by Age Group, (USD Million) 2018-2030 (USD Million)
Table 63. Norway Migraine Drugs market, by Availability, (USD Million) 2018-2030 (USD Million)
Table 64. Asia Pacific Migraine Drugs market, by region, (USD Million) 2018-2030 (USD Million)
Table 65. Asia Pacific Migraine Drugs market, by Treatment, (USD Million) 2018-2030 (USD Million)
Table 66. Asia Pacific Migraine Drugs market, by Therapeutic Class, (USD Million) 2018-2030 (USD Million)
Table 67. Aisa Pacific Migraine Drugs market, by Route of Administration, (USD Million) 2018-2030 (USD Million)
Table 68. Asia Pacific Migraine Drugs market, by Age Group, (USD Million) 2018-2030 (USD Million)
Table 69. Aisa Pacific Migraine Drugs market, by Availability, (USD Million) 2018-2030 (USD Million)
Table 70. China Migraine Drugs market, by Treatment, (USD Million) 2018-2030 (USD Million)
Table 71. China Migraine Drugs market, by Therapeutic Class, (USD Million) 2018-2030 (USD Million)
Table 72. China Migraine Drugs market, by Route of Administration, (USD Million) 2018-2030 (USD Million)
Table 73. China Migraine Drugs market, by Age Group, (USD Million) 2018-2030 (USD Million)
Table 74. China Migraine Drugs market, by Availability, (USD Million) 2018-2030 (USD Million)
Table 75. Japan Migraine Drugs market, by Treatment, (USD Million) 2018-2030 (USD Million)
Table 76. Japan Migraine Drugs market, by Therapeutic Class, (USD Million) 2018-2030 (USD Million)
Table 77. Japan Migraine Drugs market, by Route of Administration, (USD Million) 2018-2030 (USD Million)
Table 78. Japan Migraine Drugs market, by Age Group, (USD Million) 2018-2030 (USD Million)
Table 79. Japan Migraine Drugs market, by Availability, (USD Million) 2018-2030 (USD Million)
Table 80. India Migraine Drugs market, by Treatment, (USD Million) 2018-2030 (USD Million)
Table 81. India Migraine Drugs market, by Therapeutic Class, (USD Million) 2018-2030 (USD Million)
Table 82. India Migraine Drugs market, by Route of Administration, (USD Million) 2018-2030 (USD Million)
Table 83. India Migraine Drugs market, by Age Group, (USD Million) 2018-2030 (USD Million)
Table 84. India Migraine Drugs market, by Availability, (USD Million) 2018-2030 (USD Million)
Table 85. South Korea Migraine Drugs market, by Treatment, (USD Million) 2018-2030 (USD Million)
Table 86. South Korea Migraine Drugs market, by Therapeutic Class, (USD Million) 2018-2030 (USD Million)
Table 87. South Korea Migraine Drugs market, by Route of Administration, (USD Million) 2018-2030 (USD Million)
Table 88. South Korea Migraine Drugs market, by Age Group, (USD Million) 2018-2030 (USD Million)
Table 89. South Korea Migraine Drugs market, by Availability, (USD Million) 2018-2030 (USD Million)
Table 90. Australia Migraine Drugs market, by Treatment, (USD Million) 2018-2030 (USD Million)
Table 91. Australia Migraine Drugs market, by Therapeutic Class, (USD Million) 2018-2030 (USD Million)
Table 92. Australia Migraine Drugs market, by Route of Administration, (USD Million) 2018-2030 (USD Million)
Table 93. Australia Migraine Drugs market, by Age Group, (USD Million) 2018-2030 (USD Million)
Table 94. Australia Migraine Drugs market, by Availability, (USD Million) 2018-2030 (USD Million)
Table 95. Thailand Migraine Drugs market, by Treatment, (USD Million) 2018-2030 (USD Million)
Table 96. Thailand Migraine Drugs market, by Therapeutic Class, (USD Million) 2018-2030 (USD Million)
Table 97. Thailand Migraine Drugs market, by Route of Administration, (USD Million) 2018-2030 (USD Million)
Table 98. Thailand Migraine Drugs market, by Age Group, (USD Million) 2018-2030 (USD Million)
Table 99. Thailand Migraine Drugs market, by Availability, (USD Million) 2018-2030 (USD Million)
Table 100. Latin America Migraine Drugs market, by region, (USD Million) 2018-2030 (USD Million)
Table 101. Latin America Migraine Drugs market, by Treatment, (USD Million) 2018-2030 (USD Million)
Table 102. Latin America Migraine Drugs market, by Therapeutic Class, (USD Million) 2018-2030 (USD Million)
Table 103. Latin America Migraine Drugs market, by Route of Administration, (USD Million) 2018-2030 (USD Million)
Table 104. Latin America Migraine Drugs market, by Age Group, (USD Million) 2018-2030 (USD Million)
Table 105. Latin America Migraine Drugs market, by Availability, (USD Million) 2018-2030 (USD Million)
Table 106. Brazil Migraine Drugs market, by Treatment, (USD Million) 2018-2030 (USD Million)
Table 107. Brazil Migraine Drugs market, by Therapeutic Class, (USD Million) 2018-2030 (USD Million)
Table 108. Brazil Migraine Drugs market, by Route of Administration, (USD Million) 2018-2030 (USD Million)
Table 109. Brazil Migraine Drugs market, by Age Group, (USD Million) 2018-2030 (USD Million)
Table 110. Brazil Migraine Drugs market, by Availability, (USD Million) 2018-2030 (USD Million)
Table 111. Mexico Migraine Drugs market, by Treatment, (USD Million) 2018-2030 (USD Million)
Table 112. Mexico Migraine Drugs market, by Therapeutic Class, (USD Million) 2018-2030 (USD Million)
Table 113. Mexico Migraine Drugs market, by Route of Administration, (USD Million) 2018-2030 (USD Million)
Table 114. Mexico Migraine Drugs market, by Age Group, (USD Million) 2018-2030 (USD Million)
Table 115. Mexico Migraine Drugs market, by Availability, (USD Million) 2018-2030 (USD Million)
Table 116. Argentina Migraine Drugs market, by Treatment, (USD Million) 2018-2030 (USD Million)
Table 117. Argentina Migraine Drugs market, by Therapeutic Class, (USD Million) 2018-2030 (USD Million)
Table 118. Argentina Migraine Drugs market, by Route of Administration, (USD Million) 2018-2030 (USD Million)
Table 119. Argentina Migraine Drugs market, by Age Group, (USD Million) 2018-2030 (USD Million)
Table 120. Argentina Migraine Drugs market, by Availability, (USD Million) 2018-2030 (USD Million)
Table 121. MEA Migraine Drugs market, by region, (USD Million) 2018-2030 (USD Million)
Table 122. MEA Migraine Drugs market, by Treatment, (USD Million) 2018-2030 (USD Million)
Table 123. MEA Migraine Drugs market, by Therapeutic Class, (USD Million) 2018-2030 (USD Million)
Table 124. MEA Migraine Drugs market, by Route of Administration, (USD Million) 2018-2030 (USD Million)
Table 125. MEA Migraine Drugs market, by Age Group, (USD Million) 2018-2030 (USD Million)
Table 126. MEA Migraine Drugs market, by Availability, (USD Million) 2018-2030 (USD Million)
Table 127. South Africa Migraine Drugs market, by Treatment, (USD Million) 2018-2030 (USD Million)
Table 128. South Africa Migraine Drugs market, by Therapeutic Class, (USD Million) 2018-2030 (USD Million)
Table 129. South Africa Migraine Drugs market, by Route of Administration, (USD Million) 2018-2030 (USD Million)
Table 130. South Africa Migraine Drugs market, by Age Group, (USD Million) 2018-2030 (USD Million)
Table 131. South Africa Migraine Drugs market, by Availability, (USD Million) 2018-2030 (USD Million)
Table 132. Saudi Arabia Migraine Drugs market, by Treatment, (USD Million) 2018-2030 (USD Million)
Table 133. Saudi Arabia Migraine Drugs market, by Therapeutic Class, (USD Million) 2018-2030 (USD Million)
Table 134. Saudi Arabia Migraine Drugs market, by Route of Administration, (USD Million) 2018-2030 (USD Million)
Table 135. Saudi Arabia Migraine Drugs market, by Age Group, (USD Million) 2018-2030 (USD Million)
Table 136. Saudi Arabia Migraine Drugs market, by Availability, (USD Million) 2018-2030 (USD Million)
Table 137. UAE Migraine Drugs market, by Treatment, (USD Million) 2018-2030 (USD Million)
Table 138. UAE Migraine Drugs market, by Therapeutic Class, (USD Million) 2018-2030 (USD Million)
Table 139. UAE Migraine Drugs market, by Route of Administration, (USD Million) 2018-2030 (USD Million)
Table 140. UAE Migraine Drugs market, by Age Group, (USD Million) 2018-2030 (USD Million)
Table 141. UAE Migraine Drugs market, by Availability, (USD Million) 2018-2030 (USD Million)
Table 142. Kuwait Migraine Drugs market, by Treatment, (USD Million) 2018-2030 (USD Million)
Table 143. Kuwait Migraine Drugs market, by Therapeutic Class, (USD Million) 2018-2030 (USD Million)
Table 144. Kuwait Migraine Drugs market, by Route of Administration, (USD Million) 2018-2030 (USD Million)
Table 145. Kuwait Migraine Drugs market, by Age Group, (USD Million) 2018-2030 (USD Million)
Table 146. Kuwait Migraine Drugs market, by Availability, (USD Million) 2018-2030 (USD Million)
Table 2. North America Migraine Drugs market, by region, (USD Million) 2018-2030 (USD Million)
Table 3. North America Migraine Drugs market, by Treatment, (USD Million) 2018-2030 (USD Million)
Table 4. North America Migraine Drugs market, by Therapeutic Class, (USD Million) 2018-2030 (USD Million)
Table 5. North America Migraine Drugs market, by Route of Administration, (USD Million) 2018-2030 (USD Million)
Table 6. North America Migraine Drugs market, by Age Group, (USD Million) 2018-2030 (USD Million)
Table 7. North America Migraine Drugs market, by Availability, (USD Million) 2018-2030 (USD Million)
Table 8. U.S. Migraine Drugs market, by Treatment, (USD Million) 2018-2030 (USD Million)
Table 9. U.S. Migraine Drugs market, by Therapeutic Class, (USD Million) 2018-2030 (USD Million)
Table 10. U.S. Migraine Drugs market, by Route of Administration, (USD Million) 2018-2030 (USD Million)
Table 11. U.S. Migraine Drugs market, by Age Group, (USD Million) 2018-2030 (USD Million)
Table 12. U.S. Migraine Drugs market, by Availability, (USD Million) 2018-2030 (USD Million)
Table 13. Canada Migraine Drugs market, by Treatment, (USD Million) 2018-2030 (USD Million)
Table 14. Canada Migraine Drugs market, by Therapeutic Class, (USD Million) 2018-2030 (USD Million)
Table 15. Canada Migraine Drugs market, by Route of Administration, (USD Million) 2018-2030 (USD Million)
Table 16. Canada Migraine Drugs market, by Age Group, (USD Million) 2018-2030 (USD Million)
Table 17. Canada Migraine Drugs market, by Availability, (USD Million) 2018-2030 (USD Million)
Table 18. Europe Migraine Drugs market, by region, (USD Million) 2018-2030 (USD Million)
Table 19. Europe Migraine Drugs market, by Treatment, (USD Million) 2018-2030 (USD Million)
Table 20. Europe Migraine Drugs market, by Therapeutic Class, (USD Million) 2018-2030 (USD Million)
Table 21. Europe Migraine Drugs market, by Route of Administration, (USD Million) 2018-2030 (USD Million)
Table 22. Europe Migraine Drugs market, by Age Group, (USD Million) 2018-2030 (USD Million)
Table 23. Europe Migraine Drugs market, by Availability, (USD Million) 2018-2030 (USD Million)
Table 24. Germany Migraine Drugs market, by Treatment, (USD Million) 2018-2030 (USD Million)
Table 25. Germany Migraine Drugs market, by Therapeutic Class, (USD Million) 2018-2030 (USD Million)
Table 26. Germany Migraine Drugs market, by Route of Administration, (USD Million) 2018-2030 (USD Million)
Table 27. Germany Migraine Drugs market, by Age Group, (USD Million) 2018-2030 (USD Million)
Table 28. Germany Migraine Drugs market, by Availability, (USD Million) 2018-2030 (USD Million)
Table 29. UK Migraine Drugs market, by Treatment, (USD Million) 2018-2030 (USD Million)
Table 30. UK Migraine Drugs market, by Therapeutic Class, (USD Million) 2018-2030 (USD Million)
Table 31. UK Migraine Drugs market, by Route of Administration, (USD Million) 2018-2030 (USD Million)
Table 32. UK Migraine Drugs market, by Age Group, (USD Million) 2018-2030 (USD Million)
Table 33. UK Migraine Drugs market, by Availability, (USD Million) 2018-2030 (USD Million)
Table 34. France Migraine Drugs market, by Treatment, (USD Million) 2018-2030 (USD Million)
Table 35. France Migraine Drugs market, by Therapeutic Class, (USD Million) 2018-2030 (USD Million)
Table 36. France Migraine Drugs market, by Route of Administration, (USD Million) 2018-2030 (USD Million)
Table 37. France Migraine Drugs market, by Age Group, (USD Million) 2018-2030 (USD Million)
Table 38. France Migraine Drugs market, by Availability, (USD Million) 2018-2030 (USD Million)
Table 39. Italy Migraine Drugs market, by Treatment, (USD Million) 2018-2030 (USD Million)
Table 40. Italy Migraine Drugs market, by Therapeutic Class, (USD Million) 2018-2030 (USD Million)
Table 41. Italy Migraine Drugs market, by Route of Administration, (USD Million) 2018-2030 (USD Million)
Table 42. Italy Migraine Drugs market, by Age Group, (USD Million) 2018-2030 (USD Million)
Table 43. Italy Migraine Drugs market, by Availability, (USD Million) 2018-2030 (USD Million)
Table 44. Spain Migraine Drugs market, by Treatment, (USD Million) 2018-2030 (USD Million)
Table 45. Spain Migraine Drugs market, by Therapeutic Class, (USD Million) 2018-2030 (USD Million)
Table 46. Spain Migraine Drugs market, by Route of Administration, (USD Million) 2018-2030 (USD Million)
Table 47. Spain Migraine Drugs market, by Age Group, (USD Million) 2018-2030 (USD Million)
Table 48. Spain Migraine Drugs market, by Availability, (USD Million) 2018-2030 (USD Million)
Table 49. Denmark Migraine Drugs market, by Treatment, (USD Million) 2018-2030 (USD Million)
Table 50. Denmark Migraine Drugs market, by Therapeutic Class, (USD Million) 2018-2030 (USD Million)
Table 51. Denmark Migraine Drugs market, by Route of Administration, (USD Million) 2018-2030 (USD Million)
Table 52. Denmark Migraine Drugs market, by Age Group, (USD Million) 2018-2030 (USD Million)
Table 53. Denmark Migraine Drugs market, by Availability, (USD Million) 2018-2030 (USD Million)
Table 54. Sweden Migraine Drugs market, by Treatment, (USD Million) 2018-2030 (USD Million)
Table 55. Sweden Migraine Drugs market, by Therapeutic Class, (USD Million) 2018-2030 (USD Million)
Table 56. Sweden Migraine Drugs market, by Route of Administration, (USD Million) 2018-2030 (USD Million)
Table 57. Sweden Migraine Drugs market, by Age Group, (USD Million) 2018-2030 (USD Million)
Table 58. Sweden Migraine Drugs market, by Availability, (USD Million) 2018-2030 (USD Million)
Table 59. Norway Migraine Drugs market, by Treatment, (USD Million) 2018-2030 (USD Million)
Table 60. Norway Migraine Drugs market, by Therapeutic Class, (USD Million) 2018-2030 (USD Million)
Table 61. Norway Migraine Drugs market, by Route of Administration, (USD Million) 2018-2030 (USD Million)
Table 62. Norway Migraine Drugs market, by Age Group, (USD Million) 2018-2030 (USD Million)
Table 63. Norway Migraine Drugs market, by Availability, (USD Million) 2018-2030 (USD Million)
Table 64. Asia Pacific Migraine Drugs market, by region, (USD Million) 2018-2030 (USD Million)
Table 65. Asia Pacific Migraine Drugs market, by Treatment, (USD Million) 2018-2030 (USD Million)
Table 66. Asia Pacific Migraine Drugs market, by Therapeutic Class, (USD Million) 2018-2030 (USD Million)
Table 67. Aisa Pacific Migraine Drugs market, by Route of Administration, (USD Million) 2018-2030 (USD Million)
Table 68. Asia Pacific Migraine Drugs market, by Age Group, (USD Million) 2018-2030 (USD Million)
Table 69. Aisa Pacific Migraine Drugs market, by Availability, (USD Million) 2018-2030 (USD Million)
Table 70. China Migraine Drugs market, by Treatment, (USD Million) 2018-2030 (USD Million)
Table 71. China Migraine Drugs market, by Therapeutic Class, (USD Million) 2018-2030 (USD Million)
Table 72. China Migraine Drugs market, by Route of Administration, (USD Million) 2018-2030 (USD Million)
Table 73. China Migraine Drugs market, by Age Group, (USD Million) 2018-2030 (USD Million)
Table 74. China Migraine Drugs market, by Availability, (USD Million) 2018-2030 (USD Million)
Table 75. Japan Migraine Drugs market, by Treatment, (USD Million) 2018-2030 (USD Million)
Table 76. Japan Migraine Drugs market, by Therapeutic Class, (USD Million) 2018-2030 (USD Million)
Table 77. Japan Migraine Drugs market, by Route of Administration, (USD Million) 2018-2030 (USD Million)
Table 78. Japan Migraine Drugs market, by Age Group, (USD Million) 2018-2030 (USD Million)
Table 79. Japan Migraine Drugs market, by Availability, (USD Million) 2018-2030 (USD Million)
Table 80. India Migraine Drugs market, by Treatment, (USD Million) 2018-2030 (USD Million)
Table 81. India Migraine Drugs market, by Therapeutic Class, (USD Million) 2018-2030 (USD Million)
Table 82. India Migraine Drugs market, by Route of Administration, (USD Million) 2018-2030 (USD Million)
Table 83. India Migraine Drugs market, by Age Group, (USD Million) 2018-2030 (USD Million)
Table 84. India Migraine Drugs market, by Availability, (USD Million) 2018-2030 (USD Million)
Table 85. South Korea Migraine Drugs market, by Treatment, (USD Million) 2018-2030 (USD Million)
Table 86. South Korea Migraine Drugs market, by Therapeutic Class, (USD Million) 2018-2030 (USD Million)
Table 87. South Korea Migraine Drugs market, by Route of Administration, (USD Million) 2018-2030 (USD Million)
Table 88. South Korea Migraine Drugs market, by Age Group, (USD Million) 2018-2030 (USD Million)
Table 89. South Korea Migraine Drugs market, by Availability, (USD Million) 2018-2030 (USD Million)
Table 90. Australia Migraine Drugs market, by Treatment, (USD Million) 2018-2030 (USD Million)
Table 91. Australia Migraine Drugs market, by Therapeutic Class, (USD Million) 2018-2030 (USD Million)
Table 92. Australia Migraine Drugs market, by Route of Administration, (USD Million) 2018-2030 (USD Million)
Table 93. Australia Migraine Drugs market, by Age Group, (USD Million) 2018-2030 (USD Million)
Table 94. Australia Migraine Drugs market, by Availability, (USD Million) 2018-2030 (USD Million)
Table 95. Thailand Migraine Drugs market, by Treatment, (USD Million) 2018-2030 (USD Million)
Table 96. Thailand Migraine Drugs market, by Therapeutic Class, (USD Million) 2018-2030 (USD Million)
Table 97. Thailand Migraine Drugs market, by Route of Administration, (USD Million) 2018-2030 (USD Million)
Table 98. Thailand Migraine Drugs market, by Age Group, (USD Million) 2018-2030 (USD Million)
Table 99. Thailand Migraine Drugs market, by Availability, (USD Million) 2018-2030 (USD Million)
Table 100. Latin America Migraine Drugs market, by region, (USD Million) 2018-2030 (USD Million)
Table 101. Latin America Migraine Drugs market, by Treatment, (USD Million) 2018-2030 (USD Million)
Table 102. Latin America Migraine Drugs market, by Therapeutic Class, (USD Million) 2018-2030 (USD Million)
Table 103. Latin America Migraine Drugs market, by Route of Administration, (USD Million) 2018-2030 (USD Million)
Table 104. Latin America Migraine Drugs market, by Age Group, (USD Million) 2018-2030 (USD Million)
Table 105. Latin America Migraine Drugs market, by Availability, (USD Million) 2018-2030 (USD Million)
Table 106. Brazil Migraine Drugs market, by Treatment, (USD Million) 2018-2030 (USD Million)
Table 107. Brazil Migraine Drugs market, by Therapeutic Class, (USD Million) 2018-2030 (USD Million)
Table 108. Brazil Migraine Drugs market, by Route of Administration, (USD Million) 2018-2030 (USD Million)
Table 109. Brazil Migraine Drugs market, by Age Group, (USD Million) 2018-2030 (USD Million)
Table 110. Brazil Migraine Drugs market, by Availability, (USD Million) 2018-2030 (USD Million)
Table 111. Mexico Migraine Drugs market, by Treatment, (USD Million) 2018-2030 (USD Million)
Table 112. Mexico Migraine Drugs market, by Therapeutic Class, (USD Million) 2018-2030 (USD Million)
Table 113. Mexico Migraine Drugs market, by Route of Administration, (USD Million) 2018-2030 (USD Million)
Table 114. Mexico Migraine Drugs market, by Age Group, (USD Million) 2018-2030 (USD Million)
Table 115. Mexico Migraine Drugs market, by Availability, (USD Million) 2018-2030 (USD Million)
Table 116. Argentina Migraine Drugs market, by Treatment, (USD Million) 2018-2030 (USD Million)
Table 117. Argentina Migraine Drugs market, by Therapeutic Class, (USD Million) 2018-2030 (USD Million)
Table 118. Argentina Migraine Drugs market, by Route of Administration, (USD Million) 2018-2030 (USD Million)
Table 119. Argentina Migraine Drugs market, by Age Group, (USD Million) 2018-2030 (USD Million)
Table 120. Argentina Migraine Drugs market, by Availability, (USD Million) 2018-2030 (USD Million)
Table 121. MEA Migraine Drugs market, by region, (USD Million) 2018-2030 (USD Million)
Table 122. MEA Migraine Drugs market, by Treatment, (USD Million) 2018-2030 (USD Million)
Table 123. MEA Migraine Drugs market, by Therapeutic Class, (USD Million) 2018-2030 (USD Million)
Table 124. MEA Migraine Drugs market, by Route of Administration, (USD Million) 2018-2030 (USD Million)
Table 125. MEA Migraine Drugs market, by Age Group, (USD Million) 2018-2030 (USD Million)
Table 126. MEA Migraine Drugs market, by Availability, (USD Million) 2018-2030 (USD Million)
Table 127. South Africa Migraine Drugs market, by Treatment, (USD Million) 2018-2030 (USD Million)
Table 128. South Africa Migraine Drugs market, by Therapeutic Class, (USD Million) 2018-2030 (USD Million)
Table 129. South Africa Migraine Drugs market, by Route of Administration, (USD Million) 2018-2030 (USD Million)
Table 130. South Africa Migraine Drugs market, by Age Group, (USD Million) 2018-2030 (USD Million)
Table 131. South Africa Migraine Drugs market, by Availability, (USD Million) 2018-2030 (USD Million)
Table 132. Saudi Arabia Migraine Drugs market, by Treatment, (USD Million) 2018-2030 (USD Million)
Table 133. Saudi Arabia Migraine Drugs market, by Therapeutic Class, (USD Million) 2018-2030 (USD Million)
Table 134. Saudi Arabia Migraine Drugs market, by Route of Administration, (USD Million) 2018-2030 (USD Million)
Table 135. Saudi Arabia Migraine Drugs market, by Age Group, (USD Million) 2018-2030 (USD Million)
Table 136. Saudi Arabia Migraine Drugs market, by Availability, (USD Million) 2018-2030 (USD Million)
Table 137. UAE Migraine Drugs market, by Treatment, (USD Million) 2018-2030 (USD Million)
Table 138. UAE Migraine Drugs market, by Therapeutic Class, (USD Million) 2018-2030 (USD Million)
Table 139. UAE Migraine Drugs market, by Route of Administration, (USD Million) 2018-2030 (USD Million)
Table 140. UAE Migraine Drugs market, by Age Group, (USD Million) 2018-2030 (USD Million)
Table 141. UAE Migraine Drugs market, by Availability, (USD Million) 2018-2030 (USD Million)
Table 142. Kuwait Migraine Drugs market, by Treatment, (USD Million) 2018-2030 (USD Million)
Table 143. Kuwait Migraine Drugs market, by Therapeutic Class, (USD Million) 2018-2030 (USD Million)
Table 144. Kuwait Migraine Drugs market, by Route of Administration, (USD Million) 2018-2030 (USD Million)
Table 145. Kuwait Migraine Drugs market, by Age Group, (USD Million) 2018-2030 (USD Million)
Table 146. Kuwait Migraine Drugs market, by Availability, (USD Million) 2018-2030 (USD Million)
List of Figures
Figure 1 Market research process
Figure 2 Data triangulation techniques
Figure 3 Primary research pattern
Figure 4 Primary interviews in North America
Figure 5 Primary interviews in Europe
Figure 6 Primary interviews in APAC
Figure 7 Primary interviews in Latin America
Figure 8 Primary interviews in MEA
Figure 9 Market research approaches
Figure 10 Value-chain-based sizing & forecasting
Figure 11 QFD modeling for market share assessment
Figure 12 Market formulation & validation
Figure 13 Migraine Drugs market: market outlook
Figure 14 Migraine Drugs competitive insights
Figure 15 Parent market outlook
Figure 16 Related/ancillary market outlook
Figure 17 Migraine Drugs market driver impact
Figure 18 Migraine Drugs market restraint impact
Figure 19 Migraine Drugs market: Treatment movement analysis
Figure 20 Migraine Drugs market: Treatment outlook and key takeaways
Figure 21 Acute market estimates and forecast, 2018-2030 (USD Million)
Figure 22 Preventive estimates and forecast, 2018-2030 (USD Million)
Figure 23 Migraine Drugs market: Therapeutic Class movement analysis
Figure 24 Migraine Drugs market: Therapeutic Class outlook and key takeaways
Figure 25 CGRP monoclonal antibodies market estimates and forecast, 2018-2030 (USD Million)
Figure 26 CGRP small molecule antagonists market estimates and forecast, 2018-2030 (USD Million)
Figure 27 Acetylcholine inhibitors/ neurotoxins market estimates and forecast, 2018-2030 (USD Million)
Figure 28 Triptans market estimates and forecast, 2018-2030 (USD Million)
Figure 29 Ditans market estimates and forecast, 2018-2030 (USD Million)
Figure 30 Ergot alkaloids market estimates and forecast, 2018-2030 (USD Million)
Figure 31 NSAIDs market estimates and forecast, 2018-2030 (USD Million)
Figure 32 Others market estimates and forecast, 2018-2030 (USD Million)
Figure 33 Migraine Drugs market: Route of Administration movement analysis
Figure 34 Migraine Drugs market: Route of Administration outlook and key takeaways
Figure 35 Oral market estimates and forecast, 2018-2030 (USD Million)
Figure 36 Injectable market estimates and forecast, 2018-2030 (USD Million)
Figure 37 Others market estimates and forecast, 2018-2030 (USD Million)
Figure 38 Migraine Drugs market: Age Group movement analysis
Figure 39 Migraine Drugs market: Age Group outlook and key takeaways
Figure 40 Pediatric market estimates and forecast, 2018-2030 (USD Million)
Figure 41 Adult market estimates and forecast, 2018-2030 (USD Million)
Figure 42 Geriatric market estimates and forecast, 2018-2030 (USD Million)
Figure 43 Migraine Drugs market: Availability movement analysis
Figure 44 Migraine Drugs market: Availability outlook and key takeaways
Figure 45 Prescription Drugs market estimates and forecast, 2018-2030 (USD Million)
Figure 46 Over-the-Counter (OTC) Drugs market estimates and forecast, 2018-2030 (USD Million)
Figure 47 Global Migraine Drugs market: Regional movement analysis
Figure 48 Global Migraine Drugs market: Regional outlook and key takeaways
Figure 49 Global Migraine Drugs market share and leading players
Figure 50 North America market estimates and forecasts, 2018-2030 (USD Million)
Figure 51 US key country dynamics
Figure 52 US market estimates and forecasts, 2018-2030 (USD Million)
Figure 53 Canada key country dynamics
Figure 54 Canada market estimates and forecasts, 2018-2030 (USD Million)
Figure 55 Europe market estimates and forecasts, 2018-2030 (USD Million)
Figure 56 UK key country dynamics
Figure 57 UK market estimates and forecasts, 2018-2030 (USD Million)
Figure 58 Germany key country dynamics
Figure 59 Germany market estimates and forecasts, 2018-2030 (USD Million)
Figure 60 France key country dynamics
Figure 61 France market estimates and forecasts, 2018-2030 (USD Million)
Figure 62 Italy key country dynamics
Figure 63 Italy market estimates and forecasts, 2018-2030 (USD Million)
Figure 64 Spain key country dynamics
Figure 65 Spain market estimates and forecasts, 2018-2030 (USD Million)
Figure 66 Denmark key country dynamics
Figure 67 Denmark market estimates and forecasts, 2018-2030 (USD Million)
Figure 68 Sweden key country dynamics
Figure 69 Sweden market estimates and forecasts, 2018-2030 (USD Million)
Figure 70 Norway key country dynamics
Figure 71 Norway market estimates and forecasts, 2018-2030 (USD Million)
Figure 72 Asia Pacific market estimates and forecasts, 2018-2030 (USD Million)
Figure 73 China key country dynamics
Figure 74 China market estimates and forecasts, 2018-2030 (USD Million)
Figure 75 Japan key country dynamics
Figure 76 Japan market estimates and forecasts, 2018-2030 (USD Million)
Figure 77 India key country dynamics
Figure 78 India market estimates and forecasts, 2018-2030 (USD Million)
Figure 79 Thailand key country dynamics
Figure 80 Thailand market estimates and forecasts, 2018-2030 (USD Million)
Figure 81 South Korea key country dynamics
Figure 82 South Korea market estimates and forecasts, 2018-2030 (USD Million)
Figure 83 Australia key country dynamics
Figure 84 Australia market estimates and forecasts, 2018-2030 (USD Million)
Figure 85 Latin America market estimates and forecasts, 2018-2030 (USD Million)
Figure 86 Brazil key country dynamics
Figure 87 Brazil market estimates and forecasts, 2018-2030 (USD Million)
Figure 88 Mexico key country dynamics
Figure 89 Mexico market estimates and forecasts, 2018-2030 (USD Million)
Figure 90 Argentina key country dynamics
Figure 91 Argentina market estimates and forecasts, 2018-2030 (USD Million)
Figure 92 Middle East and Africa market estimates and forecasts, 2018-2030 (USD Million)
Figure 93 South Africa key country dynamics
Figure 94 South Africa market estimates and forecasts, 2018-2030 (USD Million)
Figure 95 Saudi Arabia key country dynamics
Figure 96 Saudi Arabia market estimates and forecasts, 2018-2030 (USD Million)
Figure 97 UAE key country dynamics
Figure 98 UAE market estimates and forecasts, 2018-2030 (USD Million)
Figure 99 Kuwait key country dynamics
Figure 100 Kuwait market estimates and forecasts, 2018-2030 (USD Million)
Figure 101 Market share of key market players - Migraine Drugs market
Figure 2 Data triangulation techniques
Figure 3 Primary research pattern
Figure 4 Primary interviews in North America
Figure 5 Primary interviews in Europe
Figure 6 Primary interviews in APAC
Figure 7 Primary interviews in Latin America
Figure 8 Primary interviews in MEA
Figure 9 Market research approaches
Figure 10 Value-chain-based sizing & forecasting
Figure 11 QFD modeling for market share assessment
Figure 12 Market formulation & validation
Figure 13 Migraine Drugs market: market outlook
Figure 14 Migraine Drugs competitive insights
Figure 15 Parent market outlook
Figure 16 Related/ancillary market outlook
Figure 17 Migraine Drugs market driver impact
Figure 18 Migraine Drugs market restraint impact
Figure 19 Migraine Drugs market: Treatment movement analysis
Figure 20 Migraine Drugs market: Treatment outlook and key takeaways
Figure 21 Acute market estimates and forecast, 2018-2030 (USD Million)
Figure 22 Preventive estimates and forecast, 2018-2030 (USD Million)
Figure 23 Migraine Drugs market: Therapeutic Class movement analysis
Figure 24 Migraine Drugs market: Therapeutic Class outlook and key takeaways
Figure 25 CGRP monoclonal antibodies market estimates and forecast, 2018-2030 (USD Million)
Figure 26 CGRP small molecule antagonists market estimates and forecast, 2018-2030 (USD Million)
Figure 27 Acetylcholine inhibitors/ neurotoxins market estimates and forecast, 2018-2030 (USD Million)
Figure 28 Triptans market estimates and forecast, 2018-2030 (USD Million)
Figure 29 Ditans market estimates and forecast, 2018-2030 (USD Million)
Figure 30 Ergot alkaloids market estimates and forecast, 2018-2030 (USD Million)
Figure 31 NSAIDs market estimates and forecast, 2018-2030 (USD Million)
Figure 32 Others market estimates and forecast, 2018-2030 (USD Million)
Figure 33 Migraine Drugs market: Route of Administration movement analysis
Figure 34 Migraine Drugs market: Route of Administration outlook and key takeaways
Figure 35 Oral market estimates and forecast, 2018-2030 (USD Million)
Figure 36 Injectable market estimates and forecast, 2018-2030 (USD Million)
Figure 37 Others market estimates and forecast, 2018-2030 (USD Million)
Figure 38 Migraine Drugs market: Age Group movement analysis
Figure 39 Migraine Drugs market: Age Group outlook and key takeaways
Figure 40 Pediatric market estimates and forecast, 2018-2030 (USD Million)
Figure 41 Adult market estimates and forecast, 2018-2030 (USD Million)
Figure 42 Geriatric market estimates and forecast, 2018-2030 (USD Million)
Figure 43 Migraine Drugs market: Availability movement analysis
Figure 44 Migraine Drugs market: Availability outlook and key takeaways
Figure 45 Prescription Drugs market estimates and forecast, 2018-2030 (USD Million)
Figure 46 Over-the-Counter (OTC) Drugs market estimates and forecast, 2018-2030 (USD Million)
Figure 47 Global Migraine Drugs market: Regional movement analysis
Figure 48 Global Migraine Drugs market: Regional outlook and key takeaways
Figure 49 Global Migraine Drugs market share and leading players
Figure 50 North America market estimates and forecasts, 2018-2030 (USD Million)
Figure 51 US key country dynamics
Figure 52 US market estimates and forecasts, 2018-2030 (USD Million)
Figure 53 Canada key country dynamics
Figure 54 Canada market estimates and forecasts, 2018-2030 (USD Million)
Figure 55 Europe market estimates and forecasts, 2018-2030 (USD Million)
Figure 56 UK key country dynamics
Figure 57 UK market estimates and forecasts, 2018-2030 (USD Million)
Figure 58 Germany key country dynamics
Figure 59 Germany market estimates and forecasts, 2018-2030 (USD Million)
Figure 60 France key country dynamics
Figure 61 France market estimates and forecasts, 2018-2030 (USD Million)
Figure 62 Italy key country dynamics
Figure 63 Italy market estimates and forecasts, 2018-2030 (USD Million)
Figure 64 Spain key country dynamics
Figure 65 Spain market estimates and forecasts, 2018-2030 (USD Million)
Figure 66 Denmark key country dynamics
Figure 67 Denmark market estimates and forecasts, 2018-2030 (USD Million)
Figure 68 Sweden key country dynamics
Figure 69 Sweden market estimates and forecasts, 2018-2030 (USD Million)
Figure 70 Norway key country dynamics
Figure 71 Norway market estimates and forecasts, 2018-2030 (USD Million)
Figure 72 Asia Pacific market estimates and forecasts, 2018-2030 (USD Million)
Figure 73 China key country dynamics
Figure 74 China market estimates and forecasts, 2018-2030 (USD Million)
Figure 75 Japan key country dynamics
Figure 76 Japan market estimates and forecasts, 2018-2030 (USD Million)
Figure 77 India key country dynamics
Figure 78 India market estimates and forecasts, 2018-2030 (USD Million)
Figure 79 Thailand key country dynamics
Figure 80 Thailand market estimates and forecasts, 2018-2030 (USD Million)
Figure 81 South Korea key country dynamics
Figure 82 South Korea market estimates and forecasts, 2018-2030 (USD Million)
Figure 83 Australia key country dynamics
Figure 84 Australia market estimates and forecasts, 2018-2030 (USD Million)
Figure 85 Latin America market estimates and forecasts, 2018-2030 (USD Million)
Figure 86 Brazil key country dynamics
Figure 87 Brazil market estimates and forecasts, 2018-2030 (USD Million)
Figure 88 Mexico key country dynamics
Figure 89 Mexico market estimates and forecasts, 2018-2030 (USD Million)
Figure 90 Argentina key country dynamics
Figure 91 Argentina market estimates and forecasts, 2018-2030 (USD Million)
Figure 92 Middle East and Africa market estimates and forecasts, 2018-2030 (USD Million)
Figure 93 South Africa key country dynamics
Figure 94 South Africa market estimates and forecasts, 2018-2030 (USD Million)
Figure 95 Saudi Arabia key country dynamics
Figure 96 Saudi Arabia market estimates and forecasts, 2018-2030 (USD Million)
Figure 97 UAE key country dynamics
Figure 98 UAE market estimates and forecasts, 2018-2030 (USD Million)
Figure 99 Kuwait key country dynamics
Figure 100 Kuwait market estimates and forecasts, 2018-2030 (USD Million)
Figure 101 Market share of key market players - Migraine Drugs market
Companies Mentioned
The companies profiled in this Migraine Drugs market report include:- AbbVie Inc.
- Amgen Inc.
- Teva Pharmaceutical Industries Ltd.
- GSK plc
- Eli Lilly and Company
- Pfizer Inc.
- Bausch Health Companies Inc.
- Gensco Pharma
- Impel Pharmaceuticals Inc.
- Tonix Medicines, Inc.
- Currax Pharmaceuticals LLC.
- Lundbeck
Table Information
| Report Attribute | Details |
|---|---|
| No. of Pages | 159 |
| Published | April 2025 |
| Forecast Period | 2024 - 2030 |
| Estimated Market Value ( USD | $ 6.81 Billion |
| Forecasted Market Value ( USD | $ 13.34 Billion |
| Compound Annual Growth Rate | 10.9% |
| Regions Covered | Global |
| No. of Companies Mentioned | 13 |
